tiprankstipranks
Advertisement
Advertisement

CADL Stock Latest News

Analyst Reiterates Buy Rating on Strengthened Phase 3 Data for Aglatimagene Besadenovec, Maintains $23 Price Target
RatingsAnalyst Reiterates Buy Rating on Strengthened Phase 3 Data for Aglatimagene Besadenovec, Maintains $23 Price Target
6d ago
CADL
Candel Therapeutics publishes pivotal Phase 3 data for Aglatimagene
PremiumThe Fly
Candel Therapeutics publishes pivotal Phase 3 data for Aglatimagene
6d ago
CADL
Candel Therapeutics price target raised to $9 from $7 at BofA
PremiumThe Fly
Candel Therapeutics price target raised to $9 from $7 at BofA
21d ago
CADL
Candel Therapeutics Highlights Phase 3 Prostate Cancer Data
PremiumCompany Announcements
Candel Therapeutics Highlights Phase 3 Prostate Cancer Data
24d ago
8K
CADL
Candel Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Candel Therapeutics initiated with an Overweight at Cantor Fitzgerald
2M ago
CADL
Candel Therapeutics price target raised to $26 from $22 at Citi
PremiumThe FlyCandel Therapeutics price target raised to $26 from $22 at Citi
3M ago
CADL
CAN-2409’s Emerging Survival Benefit and Biomarker-Driven Immunotherapy Platform Support Buy Rating and $23 Target
Premium
Ratings
CAN-2409’s Emerging Survival Benefit and Biomarker-Driven Immunotherapy Platform Support Buy Rating and $23 Target
3M ago
CADL
Candel Therapeutics’ aglatimagene shows extended long-term survival in NSCLC
Premium
The Fly
Candel Therapeutics’ aglatimagene shows extended long-term survival in NSCLC
3M ago
CADL
Candel Therapeutics: Strengthened Balance Sheet and Late‑Stage Pipeline Catalysts Support High‑Risk Buy Rating Despite Dilution
PremiumRatings
Candel Therapeutics: Strengthened Balance Sheet and Late‑Stage Pipeline Catalysts Support High‑Risk Buy Rating Despite Dilution
3M ago
CADL
Candel Therapeutics price target lowered to $22 from $24 at Citi
PremiumThe Fly
Candel Therapeutics price target lowered to $22 from $24 at Citi
3M ago
CADL
Restrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk
PremiumCompany Announcements
Restrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk
3M ago
CADL
Candel Therapeutics: Advancing CAN-2409 Toward a 2026 BLA on Strengthening Prostate Cancer Data and Solid Cash Runway
PremiumRatings
Candel Therapeutics: Advancing CAN-2409 Toward a 2026 BLA on Strengthening Prostate Cancer Data and Solid Cash Runway
3M ago
CADL
Candel Therapeutics: Advancing CAN-2409 Toward BLA With Platform-Like Oncology Potential and Diversified Pipeline Upside
PremiumRatingsCandel Therapeutics: Advancing CAN-2409 Toward BLA With Platform-Like Oncology Potential and Diversified Pipeline Upside
3M ago
CADL
Candel Therapeutics reports Q4 EPS (54c) vs. (40c) last year
Premium
The Fly
Candel Therapeutics reports Q4 EPS (54c) vs. (40c) last year
3M ago
CADL
Candel Therapeutics sees cash runway into 1Q28
Premium
The Fly
Candel Therapeutics sees cash runway into 1Q28
3M ago
CADL
Candel Therapeutics Announces Equity Offering to Fund CAN-2409
PremiumCompany Announcements
Candel Therapeutics Announces Equity Offering to Fund CAN-2409
4M ago
8K
CADL
Candel Therapeutics 18.3M share Spot Secondary priced at $5.45
PremiumThe Fly
Candel Therapeutics 18.3M share Spot Secondary priced at $5.45
4M ago
CADL
Candel Therapeutics 18.3M share Spot Secondary priced at $5.45
PremiumThe Fly
Candel Therapeutics 18.3M share Spot Secondary priced at $5.45
4M ago
CADL
Candel Therapeutics announces $100M royalty funding agreement
PremiumThe Fly
Candel Therapeutics announces $100M royalty funding agreement
4M ago
CADL
Candel Therapeutics Secures $100M Royalty Funding for CAN-2409
PremiumCompany AnnouncementsCandel Therapeutics Secures $100M Royalty Funding for CAN-2409
4M ago
8K
CADL
Candel Therapeutics announces $100M common stock offering
Premium
The Fly
Candel Therapeutics announces $100M common stock offering
4M ago
CADL
Candel Therapeutics Advances Gene-Based Prostate Cancer Trial With New Biomarker Update
Premium
Company Announcements
Candel Therapeutics Advances Gene-Based Prostate Cancer Trial With New Biomarker Update
4M ago
CADL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >